BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27778
- Registration Number
- NCT03484260
- Locations
- 🇩🇪
Many Locations, Berlin, Germany
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
Phase 1
Completed
- Conditions
- Hemophilia A; Hemophilia B
- Interventions
- Drug: BAY1093884
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT03481946
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Ramat Gan, Israel
A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
Phase 3
Terminated
- Conditions
- Uterine Fibroids and Heavy Menstrual Bleeding
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 153
- Registration Number
- NCT03476928
- Locations
- 🇯🇵
Kyoritsu Narashinodai Hospital, Funabashi, Chiba, Japan
🇯🇵Akazawa Clinic, Fuchu, Tokyo, Japan
🇯🇵Kurashiki Medical Clinic, Kurashiki, Okayama, Japan
Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Other: Data Collection
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 10528
- Registration Number
- NCT03474757
- Locations
- 🇨🇴
Many Locations, Multiple Locations, Colombia
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 37
- Registration Number
- NCT03473756
- Locations
- 🇯🇵
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan
🇦🇹Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria
🇦🇹Krankenhaus der Barmherzigen Brüder, Vienna, Wien, Austria
A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America
Completed
- Conditions
- Macular Degeneration
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 643
- Registration Number
- NCT03470103
- Locations
- 🇲🇽
Many locations, Multiple Locations, Mexico
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Bayer
- Target Recruit Count
- 249
- Registration Number
- NCT03462446
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Phase 1
Terminated
- Conditions
- RhabdomyosarcomaOsteosarcomaEwing SarcomaNeuroblastomaRelapsed or Refractory Solid Tumors or Lymphoma in Children
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 31
- Registration Number
- NCT03458728
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸The Children's Hospital, Aurora, Colorado, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 552
- Registration Number
- NCT03455439
- Locations
- 🇪🇸
Many Locations, Multiple Locations, Spain
A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea
Phase 4
Completed
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 201
- Registration Number
- NCT03448536
- Locations
- 🇺🇸
Synexus US, LP- Plano, Plano, Texas, United States
🇺🇸Radiant Research, Inc., Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath